Europe Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)
The Europe human vaccine adjuvants market was valued at US$ 472.33 million in 2022 and is expected to reach US$ 1,338.00 million by 2030; it is estimated to register a CAGR of 13.9% from 2022 to 2030.
Rising Trend of Personalized Vaccines Drives Europe Human Vaccine Adjuvants Market
Precision or personalized vaccines are a growing trend in the Europe human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.
Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the Europe human vaccine adjuvants market.
Europe Human Vaccine Adjuvants Market Overview
Germany is one of the top pharmaceutical markets in Europe and worldwide. According to Germany Trade & Invest (GTAI), it is the biggest pharmaceutical manufacturing location in the European Union, with approximately 600 pharmaceutical companies. According to GTAI, pharmaceutical production volume in Germany reached ~US$ 61.8 billion (~ 56.5 billion) in 2022. Further, the country ranks second in biopharmaceutical production after the US, which is attributed to favorable industrial infrastructure, a sustainably growing local chemicals industry, and highly qualified workforce availability. According to the same source, the pharmaceutical industry in Germany invested almost US$ 9.5 billion (~ 8.8 billion) in R&D in 2021, which is higher than the amounts invested in the R&D of any other industry. Catering to the largest population in Europe, Germany's healthcare sector is a highly attractive market with significant growth opportunities. A steady increase in life expectancy levels has led to a rise in chronic and age-related illnesses. An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. For instance, according to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, Germany has a population of 36.6 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Additionally, Germany has a high prevalence of hepatitis. Improved health awareness due to the prevalence of infectious diseases has further increased consumer demand for drugs, vaccines, and therapies. Thus, the demand for human vaccine adjuvants is growing rapidly in Germany with the flourishing pharmaceutical R&D landscape in pharmaceutical companies, alongside the increasing prevalence of infectious diseases.
Europe Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
Europe Human Vaccine Adjuvants Market Segmentation
The Europe human vaccine adjuvants market is categorized into type, application, end user, and country.
Based on type, the Europe human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
In terms of application, the Europe human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.
By end user, the Europe human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
By country, the Europe human vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe human vaccine adjuvants market share in 2022.
Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Europe human vaccine adjuvants market.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.1 Europe Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market - Europe Market Analysis
5.1 Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Europe Human Vaccine Adjuvants Market Forecast Analysis
6. Europe Human Vaccine Adjuvants Market Analysis - by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Human Vaccine Adjuvants Market Analysis - by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human Papilloma Virus (HPV)
7.3.1 Overview
7.3.2 Human Papilloma Virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Human Vaccine Adjuvants Market Analysis - by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Human Vaccine Adjuvants Market - Country Analysis
9.1 Europe
9.1.1 Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Germany Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 Germany Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 Germany Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 UK Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 UK Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 UK Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 France Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 France Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 France Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.4 Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Italy Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.4.2 Italy Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.4.3 Italy Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.5 Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.1 Spain Vaccine Adjuvants Market Breakdown, by Type
9.1.1.5.2 Spain Vaccine Adjuvants Market Breakdown, by Application
9.1.1.5.3 Spain Vaccine Adjuvants Market Breakdown, by End User
9.1.1.6 Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.1 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.6.2 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.6.3 Rest of Europe Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Dynavax Technologies Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 CSL Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Seppic SA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 SPI Pharma Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Croda International Plc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Novavax Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Phibro Animal Health Corp
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Creative Biolabs Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Europe Human Vaccine Adjuvants Market Segmentation
Table 2. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market
List of Figures
Figure 1. Europe Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Europe Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Europe Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Germany Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. UK Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. France Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Italy Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. Spain Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Europe Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
1. Creative Biolabs Inc
2. Croda International Plc
3. CSL Ltd
4. Dynavax Technologies Corp
5. Novartis AG
6. Novavax Inc
7. Phibro Animal Health Corp
8. Seppic SA
9. SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human vaccine adjuvants market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe human vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.